RDAF Newsletter

    13 Jul, 2023

    We just released the first issue of the RDAF newsletter, which gives an overview of key policy developments and RDAF activities in the first half of the year.

    Highlights include:

    • Overview of the latest policy developments relevant for the rare disease field
    • Establishment of the permanent subgroup on orphan drug pricing & reimbursement
    • RDAF events
    • Outlook on planned activities for the second half of the year, including our multi-stakeholder workshop on post-marketing registries for rare diseases

    The full newsletter is available here.

    Continue reading

    Boehringer Ingelheim joins the Rare Disease Action Forum

    We are delighted to announce Boehringer Ingelheim as new member of the Rare Disease Action Forum. Boehringer Ingelheim’s membership fortifies RDAF's multi-stakeholder base, alongside other members from industry, patient organizations, healthcare professionals, and...